Investors should monitor the upcoming FDA Type B meeting in Q2 2026 for confirmation of Phase 3 trial design, which will be a key catalyst. The compelling efficacy and tolerability data position aleniglipron as a leading oral GLP-1 candidate, potentially reducing reliance on injectables and expanding market access.
GPCR drugs
GPCR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $56.65entry
- T+1 · 8mo ago −0.88%α −1.15% · $56.15
- T+5 · 8mo ago −13.40%α −11.36% · $49.06
- T+20 · 7mo ago −6.05%α −9.83% · $53.22
- T+60 · 5mo ago −33.33%α −43.81% · $37.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Structure Therapeutics announced positive Phase 2 results for aleniglipron, an oral GLP-1 receptor agonist, showing placebo-adjusted weight loss of up to 16.3% (39 lbs) at 44 weeks, the highest reported efficacy among oral GLP-1RAs and comparable to injectable versions. The data support advancement into Phase 3 trials, with an FDA end-of-Phase 2 meeting scheduled for Q2 2026 and trial initiation expected in H2 2026.
Key Facts
- Aleniglipron achieved placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks in the ACCESS II study (p<0.0001).
- In the open-label extension, weight loss reached up to 16.2% (40.5 lbs) at 56 weeks with no evidence of plateau.
- Low discontinuation rates (2.0–3.4%) due to adverse events with the 2.5 mg starting dose support improved tolerability.
- Phase 3 initiation remains on track for second half of 2026, following an FDA End-of-Phase 2 meeting in Q2 2026.
- No drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation observed across >625 participants.
Financial Impact
High potential commercial value given best-in-class oral GLP-1RA profile with injectable-like efficacy; could capture significant share of multi-billion-dollar obesity market.
Risk Factors
- Phase 3 trial delays or design changes following FDA feedback.
- Lack of head-to-head comparison with leading injectable GLP-1s like semaglutide or tirzepatide.
- Potential shift in safety or efficacy profile in larger, longer-term studies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256111 |
Track record
10 reports on GPCR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $21.73 Now $18.57 −14.54% settles Feb 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $19.08 Now $18.57 −2.67% settles Feb 3
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $43.30 to $47.34 Now $18.57 +57.11% ▼ −9.33% −4.93% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Entry $39.10 to $49.64 Now $18.57 −52.51% ▲ +26.96% +22.12% vs SPY
- Apr 27, 202629w ago Press Release Neutral 2/10 Entry $43.56 to $50.80 Now $18.57 −57.37% ▲ +16.62% +12.63% vs SPY
- Apr 15, 202630w ago 8-K Neutral 3/10 Entry $54.25 to $53.36 Now $18.57 −65.77% ▼ −1.64% −9.78% vs SPY
- Mar 16, 202635w ago Press Release Bullish 8/10 Viewing Entry $56.65 to $37.77 Now $18.57 −67.22% ▼ −33.33% −43.81% vs SPY
- Feb 28, 202637w ago Institutional Cluster Mixed 6/10 Entry $62.90 to $39.58 Now $18.57 −70.48% ▼ −37.07% −46.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers